Drug Trial Radar · NCT00843934
Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 19, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 2009
Primary completion
Dec 2012
Study completion Feb 2015
Sponsor
- Lead sponsor
- Nihon UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).
Conditions
- Carcinoma, Hepatocellular
Interventions
epirubicinDrug
Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
CisplatinDrug
Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- response rateTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Digestive Surgery, Nihon University School of Medicine
tabashi City, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.